How a European Biotech's Big Funding Round Fuels a Sustainable Protein Scale-Up

Jan de Vries · 2026-08-25

There's a quiet but powerful shift happening in how we think about our food. And a recent funding round for a European startup might just be a sign of things to come. MAASH, a fermentation company based in Brussels, has secured a major funding package worth approximately $13.1 million. This isn't just venture capital chasing a trend. It's a mix of equity investment and strategic public financing designed to do one thing: take a sustainable protein ingredient from the lab to the factory floor. ### Breaking Down the Funding So, where's the money coming from? It's a real vote of confidence from both private and public sectors. - About $6.3 million in equity came from five new investors, including Ambra Capital, InvestPro, and Bpifrance. - Another $4.6 million came as support from Bpifrance's Première Usine program. - Finally, a $2.2 million loan from Bpifrance, backed by the France 2030 initiative, rounds out the package. Frédéric Van Gansberghe, the company's co-founder and Chairman, put it simply: this combination of their expertise and new partnerships means they can move faster. Much faster. ### What MAASH Actually Does Founded in 2021, MAASH is in the business of mycoprotein. Think of it as a high-quality, sustainable protein made through precision fermentation. They're not selling you a burger. They're selling the key ingredient to food companies who want to make better burgers, sausages, or meatless options. Their secret sauce, called LoCylia, is all about control. They fine-tune the fermentation process—temperature, pH, oxygen—to get the best yield without sacrificing the texture or taste. That's crucial because if the ingredient doesn't feel right in your mouth, it doesn't matter how sustainable it is. The goal is B2B. They work with food manufacturers to either enhance existing products, reduce meat content by 10-30%, or create entirely new vegan and vegetarian lines. ### Leadership and The Road to Industrial Scale A funding round often signals a new chapter, and MAASH is making that literal with a major leadership hire. Samah Garringer, with over 25 years in food, ingredients, and scale-up at companies like DSM, is set to become CEO in September 2026. > “I am thrilled to join MAASH at this pivotal moment,” Garringer said. “Together with the team and our new partners, we will... build a resilient, cost-competitive platform to bring nutritious, sustainable mycoprotein to market at scale.” Meanwhile, co-founder Gaspard Gilbert is shifting to Chief Commercial Officer, focusing on partnerships and strategy. He highlighted the journey from acquiring an old industrial site to now having a credible, executable plan. This funding, he says, is the step that moves them from preparation to real deployment. ### What the Money Will Build This is where it gets concrete. The capital has a clear mission: launch a 424-cubic-foot demonstration plant in Carling-Saint-Avold, France. That's the crucial pre-industrial step. It proves the process works outside a lab. The ultimate target? Scaling up to an annual production of 11,000 tons. That's a serious amount of protein. It represents a shift from a promising startup project to a genuine industrial supplier. For professionals watching the alternative protein space, especially in Europe, moves like this are worth noting. It’s not just about the science anymore. It’s about building the factories, securing the partnerships, and putting the leadership in place to make sustainable food a commercial reality. This funding round for MAASH is a tangible step down that road.